Arbutus Biopharma vs Regenxbio
Regenxbio is the larger business, with $170m of revenue in fiscal 2025 against $14.1m for Arbutus Biopharma (12.1 times as much). Arbutus Biopharma grew faster (128.2% against 104.5%). Regenxbio kept more of each dollar of sales as profit: a net margin of -113.8% against -237.9%. Arbutus Biopharma carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Arbutus BiopharmaABUS, 2025 | RegenxbioRGNX, 2025 |
|---|---|---|
| Revenue | $14.1m | $170m |
| Revenue growth | 128.2% | 104.5% |
| Net income | −$33.5m | −$194m |
| Operating margin | -271.0% | -94.6% |
| Net margin | -237.9% | -113.8% |
| Return on equity | -38.5% | -107.0% |
| Free cash flow | −$39.6m | −$126m |
| Cash | $18.0m | $34.5m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 371 |
| Market value | $771m | $408m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 19 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 5 sales |